Figure 1 -

Eupraxia Pharmaceuticals Inc.

Patient SDI Clinical Remission Rates from baseline to 52 weeks in Cohorts 5-9 of the Phase 1b/2a portion of the RESOLVE trial. Chart includes only patients that have been followed for 52 weeks.

Format

JPEG

Source

Eupraxia Pharmaceuticals Inc.

Downloads